Compare

Rezolute, Inc. vs Korro Bio, Inc. vs Milestone Pharmaceuticals Inc. vs Avalo Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearRezolute, Inc.
RZLT
Korro Bio, Inc.
KRRO
Milestone Pharmaceuticals Inc.
MIST
Avalo Therapeutics, Inc.
AVTX
Year ended2026-06-302025-12-312025-12-312025-12-31
Revenuen/a$6.39Mn/a$59.0K
Revenue growth (YoY)n/a+181.5%n/a-86.6%
Gross marginn/an/an/an/a
Operating marginn/an/mn/an/m
Net marginn/an/mn/an/m
Net income-$77.59M-$117.26M-$63.06M-$78.26M
EPS (Diluted)-$0.75-$12.48-$0.75-$5.84
Operating cash flow-$64.64M-$78.56M-$49.04M-$51.46M
Free cash flown/a-$79.08M-$49.34Mn/a
Cash & equivalents$10.62M$21.82M$73.05M$15.86M
Total assets$112.85M$113.51M$113.56M$116.46M
Total liabilities$12.16M$62.07M$71.79M$33.41M
Shareholders' equity$100.69M$51.44M$41.77M$83.05M
Return on year-end equity-77.1%-228.0%-151.0%-94.2%
Shares outstanding96.41M9.42M106.24M18.51M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearRezolute, Inc.Korro Bio, Inc.Milestone Pharmaceuticals Inc.Avalo Therapeutics, Inc.
Latestn/a$6.39M
Ended 2025-12-31
n/a$59.0K
Ended 2025-12-31
1 year earliern/a$2.27M
Ended 2024-12-31
n/a$441.0K
Ended 2024-12-31
2 years earliern/a$0
Ended 2023-12-31
n/a$1.92M
Ended 2023-12-31
3 years earliern/an/an/a$18.05M
Ended 2022-12-31
4 years earliern/an/an/a$5.40M
Ended 2021-12-31